SCHEMBL25664308

SCHEMBL25664308

C[C@@H]1[C@@H]2CC(CN1C(=O)[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C)(C)C)C2(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 6/20 0.36
PSEN2 P49810 6/20 0.36
APH1B Q8WW43 6/20 0.36
NCSTN Q92542 6/20 0.36
APH1A Q96BI3 6/20 0.36
PSENEN Q9NZ42 6/20 0.36
HTRA1 Q92743 1/20 0.35
ALDH1A1 P00352 4/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 3/20 0.34
TDP1 Q9NUW8 1/20 0.34
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR6 P50406 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
F10 P00742 1/20 0.33
BMP1 P13497 1/20 0.32
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25664645 0.91 ALDH1A1 (0.35) ALDH1A1HTTLMNAKMT2A
SCHEMBL25880993 0.90 ALDH1A1 (0.34) ALDH1A1HTTLMNAKMT2A
SCHEMBL25664883 0.88 ALDH1A1 (0.33) ALDH1A1HTTLMNAKMT2AL3MBTL1
SCHEMBL25877474 0.88 PSEN1 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL25664887 0.87 ALDH1A1 (0.33) ALDH1A1HTTLMNAKMT2A
SCHEMBL25664655 0.84 CYP19A1 (0.30)
SCHEMBL25664618 0.83 MMP13 (0.43) ALDH1A1HTTLMNAHTR6F10
SCHEMBL25881023 0.82
SCHEMBL25664722 0.82
SCHEMBL26270003 0.82 ALDH1A1 (0.36) ALDH1A1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760722-B2 Inhibitors of cysteine proteases and methods of use thereof ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-09-19 US disclosed
US-20230159451-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159451-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF SERPINB1, CTSV, CTSE PSEN1 1491/4885PSEN2 1985/4885APH1B 1358/4885
US-11760722-B2 Inhibitors of cysteine proteases and methods of use thereof SERPINB1, PREP, DNPEP PSEN1 1310/4885PSEN2 1932/4885APH1B 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.